Back to Cell Types

PaTu 8988sHomo sapiens (Human)Cancer cell line

Also known as: PA-TU S, PATU-S, PATU-8988S, PaTu-8988s, PaTu 8988 S, PATU8988S, PaTu8988S, PaTu8988s, PA-TU-8988S

🤖 AI SummaryBased on 12 publications

Quick Overview

Human pancreatic cancer cell line with known genetic alterations and metastatic potential.

Detailed Summary

PaTu 8988s is a human pancreatic cancer cell line derived from a primary tumor. It exhibits distinct genetic alterations, including amplifications and deletions, which are characteristic of pancreatic carcinomas. This cell line is used in research to study the molecular mechanisms of pancreatic cancer, including the role of specific genes in tumor progression and metastasis. The cell line has been characterized for its ability to form tumors in nude mice, showing a solid growth pattern with limited polar organization of the cytoplasm. It is also noted for its potential in studying the effects of genetic mutations on protein expression and drug sensitivity.

Research Applications

Genomic profiling of pancreatic cancerStudy of gene copy number alterationsInvestigation of metabolic subtypes in pancreatic cancerAnalysis of drug sensitivity and resistanceCharacterization of tumor metastasis potential

Key Characteristics

Amplifications and deletions in genomic regionsExpression of specific oncogenes and tumor suppressorsMetastatic potential in nude miceUse in studying pancreatic cancer biology

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1846
Species	Homo sapiens (Human)
Tissue Source	Liver[UBERON:UBERON_0002107]

Donor Information

Age	64
Age Category	Adult
Sex	Female

Disease Information

Disease	Pancreatic adenocarcinoma
Lineage	Pancreas
Subtype	Pancreatic Adenocarcinoma
OncoTree Code	PAAD

DepMap Information

Source Type	DSMZ
Source ID	ACH-000022_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg282Trp (c.844C>T)	Unspecified	-	PubMed=21173094, PubMed=1373872
MutationSimple	KRAS	p.Gly12Val (c.35G>T)	Heterozygous	Acquired	Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

11,13

D13S317

12,13

D16S539

11,12

D18S51

12

D19S433

14,15

D21S11

26

D2S1338

23

D3S1358

15,17

D5S818

11,13

D7S820

7,8

D8S1179

13,16

FGA

23

Penta D

8

Penta E

13

TH01

6

TPOX

8,11

vWA

16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Linnartz R., Zubel A., Slamon D.J., Finn R.S.

Br. J. Cancer 111:1788-1801(2014).

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.

Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.

Oncogene 24:1794-1801(2005).

Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.

Veltman J.A., van Kessel A.G., Hoglund M.

Cancer Res. 64:3052-3059(2004).

Immunocytochemical analysis of cell lines derived from solid tumors.

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

J. Histochem. Cytochem. 49:1369-1378(2001).

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma.

Arnold R.

Gastroenterology 106:1645-1651(1994).

Establishment and characterisation of two cell lines with different grade of differentiation derived from one primary human pancreatic adenocarcinoma.

Elsasser H.-P., Lehr U., Agricola B., Kern H.F.

Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 61:295-306(1992).

Distribution of characteristic mutations in native ductal adenocarcinoma of the pancreas and pancreatic cancer cell lines.

Saeger H.-D.

Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013).

Web Resources

dpsc.ccbr.utoronto.ca tcpaportal.org